BR112021000279A8 - formulações de redução de tumor e métodos de uso das mesmas - Google Patents

formulações de redução de tumor e métodos de uso das mesmas

Info

Publication number
BR112021000279A8
BR112021000279A8 BR112021000279A BR112021000279A BR112021000279A8 BR 112021000279 A8 BR112021000279 A8 BR 112021000279A8 BR 112021000279 A BR112021000279 A BR 112021000279A BR 112021000279 A BR112021000279 A BR 112021000279A BR 112021000279 A8 BR112021000279 A8 BR 112021000279A8
Authority
BR
Brazil
Prior art keywords
methods
tumor reduction
formulations
reduction formulations
relates
Prior art date
Application number
BR112021000279A
Other languages
English (en)
Other versions
BR112021000279A2 (pt
Inventor
Rothman John
Hoffman Steven
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of BR112021000279A2 publication Critical patent/BR112021000279A2/pt
Publication of BR112021000279A8 publication Critical patent/BR112021000279A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

a invenção se refere a composições para redução de tumor e métodos das mesmas. especificamente, a invenção se refere a composições que compreendem uma combinação de um agente esclerosante e um agente penetrante.
BR112021000279A 2018-07-09 2019-07-02 formulações de redução de tumor e métodos de uso das mesmas BR112021000279A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695613P 2018-07-09 2018-07-09
US62/695,614 2018-07-09
PCT/US2019/040264 WO2020023191A1 (en) 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof

Publications (2)

Publication Number Publication Date
BR112021000279A2 BR112021000279A2 (pt) 2021-04-06
BR112021000279A8 true BR112021000279A8 (pt) 2021-04-20

Family

ID=75267393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021000279A BR112021000279A8 (pt) 2018-07-09 2019-07-02 formulações de redução de tumor e métodos de uso das mesmas

Country Status (11)

Country Link
EP (1) EP3820482A4 (pt)
JP (1) JP2021530482A (pt)
KR (1) KR20220098082A (pt)
CN (1) CN112584841A (pt)
AU (1) AU2019309757A1 (pt)
BR (1) BR112021000279A8 (pt)
CA (1) CA3105717A1 (pt)
EA (1) EA202190201A1 (pt)
IL (1) IL280000A (pt)
PH (1) PH12021550033A1 (pt)
WO (1) WO2020023191A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3140042A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
WO2021119096A1 (en) * 2019-12-09 2021-06-17 Tyme, Inc. Pharmaceutical compositions and methods
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007519725A (ja) * 2004-01-29 2007-07-19 バクスター・インターナショナル・インコーポレイテッド 中枢神経系への増加した送達のための抗レトロウイルス因子のナノ懸濁物
WO2006099685A1 (en) * 2005-03-24 2006-09-28 Medical Therapies Limited Method for the prophylaxis or treatment of carcinomas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
CA2954041A1 (en) * 2014-07-11 2016-01-14 The Regents Of The University Of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
US9687528B2 (en) * 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations
CA3016446A1 (en) * 2016-03-15 2017-09-21 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer

Also Published As

Publication number Publication date
PH12021550033A1 (en) 2021-09-20
EP3820482A4 (en) 2022-03-23
EA202190201A1 (ru) 2021-04-09
BR112021000279A2 (pt) 2021-04-06
KR20220098082A (ko) 2022-07-11
CA3105717A1 (en) 2020-01-30
IL280000A (en) 2021-03-01
CN112584841A8 (zh) 2021-06-18
EP3820482A1 (en) 2021-05-19
JP2021530482A (ja) 2021-11-11
WO2020023191A1 (en) 2020-01-30
AU2019309757A1 (en) 2021-03-04
CN112584841A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MX2023010042A (es) Polinucleotidos moduladores.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2018003898A (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas.
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
SV2018005643A (es) Composiciones de insulina de rapida accion
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
BR112017022089A2 (pt) uso de uma composição, e, método para branqueamento de dentes
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
BR112021000279A8 (pt) formulações de redução de tumor e métodos de uso das mesmas
BR112017004953A2 (pt) imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
BR112017019352A2 (pt) composições tópicas comprimidas a corticosteróide aplicações relacionadas
CL2020002624A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables.
UY36460A (es) Pirazolpiridinaminas
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
CL2019002514A1 (es) Composiciones cosméticas para el cuidado de la piel.
BR112018074820A2 (pt) surfactantes não iónicos para a redução de tecido adiposo
BR112018010692A8 (pt) composições imunoestimuladoras, usos de melanina ou de um precursor da melanina e método para obter uma composição imunoestimuladora
BR112018006560A2 (pt) composições para higiene bucal e métodos de uso das composições.
MX2021000314A (es) Formulaciones reductoras de tumores y metodos de uso de las mismas.
CR20180456A (es) Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
BR112017019154A2 (pt) uso de frações isoladas de goma mástica para o tratamento de neuropatia óptica

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements